Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Early warrant exercise

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Dec 29, 2023 8:27am

395 Views

Post# 35803698

Early warrant exercise

i do not think this is good for the stock price. dan throws a monkey wrench into the stock price getting much traction if any ahead of jan/18th to mid febuary.

When a warrant is exercised, the company issues new shares, increasing the total number of shares outstanding, which has a dilutive effect.

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for Nov. 11, 2024